Home > Insider Trading > Filing (0001209191-15-010373)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1609351	Spark Therapeutics Inc.	ONCE	Biological Products, (No Disgnostic Substances) (2836)	462654405

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1202294	Elliot Sigal	C/O Spark Therapeutics, Inc. 3737 Market Street, Suite 1300 Philadelphia PA 19104		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-02-04	31,559	$0.00	31,559	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2015-02-04	5,000	$23.00	11,214	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Acquisiton	2015-02-04	503	$0.00	503	$0.00
Common Stock	Series B Preferred Stock	Disposition	2015-02-04	31,559	$0.00	31,559	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
31,559			No	4	A	Indirect
0			No	4	C	Indirect

Footnotes

These shares are held by Sigal Family Investments LLC. Elliott Sigal, a member of the issuer's board of directors, is a manager of Sigal Family Investments LLC and may be deemed to have voting and investment power over the shares held by Sigal Family Investments LLC. Dr. Sigal disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
Shares of Series B Preferred Stock, while outstanding, accrued stock dividends payable in additional shares of Series B Preferred Stock at a rate of 8% per annum from November 23, 2014. These accrued stock dividends became payable in connection with the closing of the issuer's initial public offering pursuant to a registration statement on Form S-1 under the Securities Act of 1933, as amended (the "IPO"). The outstanding shares of Series B Preferred Stock, including the 503 shares issued as accrued stock dividends, converted into Spark Therapeutics, Inc. common stock upon the closing of the issuer's IPO, and have no expiration date.